Opioid-Induced Constipation Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers Global Opioid Induced Constipation Treatment Market & OIC Medication and it is Segmented by Drug Class (Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, and Others), Prescription Type (Over The Counter, Prescription), End-User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above segments.

Opioid-Induced Constipation Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Opioid Induced Constipation (OIC) Industry Overview

The Opioid Induced Constipation market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, while others are developing new methods for the treatment and introducing new products to maintain their market share. A few of the major players currently dominating the industry in terms of revenue are AstraZeneca plc, Mallinckrodt Pharmaceuticals, Bausch Health (Salix Pharmaceuticals Inc), Merck & Co Inc, and Shionogi & Co Ltd.

Opioid Induced Constipation (OIC) Market Leaders

  1. AstraZeneca plc

  2. Merck & Co Inc

  3. Shionogi & Co Ltd

  4. Mallinckrodt Pharmaceuticals

  5. Bausch Health ( Salix Pharmaceutical Inc.)

  6. *Disclaimer: Major Players sorted in no particular order
CL-OICM.png

Opioid-Induced Constipation Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?